Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
LIFT-AD Phase 2/3 Failure The larger LIFT-AD trial fails both primary and key secondary endpoints, raising questions about the clinical viability of fosgonimeton
Ferroptosis and necroinflammation, a yet poorly explored link
This means a lot of products and ingredients that consumers might assume are safe, including energy drinks, may have little to no independent safety data or information about their long-term effects, Ronholm says
Additional information Competing interests The authors declare that they have no competing interests
Obesity (Silver Spring) 33, 16571667
US$ 21.94
US$ 29.44
US$ 25.25
US$ 20.47
US$ 23.54
US$ 22.08
US$ 24.04
US$ 29.56
US$ 27.48
US$ 22.90
US$ 21.19
US$ 24.07
